FRANKLIN LAKES, N.J., and
WAGENINGEN, The Netherlands,
Jan. 15, 2018 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, along with Check-Points Health B.V.,
announced today that the companies obtained CE Mark for a
next-generation molecular screening test for antibiotic-resistant
carbapenemase-producing organisms (CPOs) on the fully-automated BD
MAX™ System.
It is estimated by the year 2050, as many as 10 million people
could die annually from antimicrobial resistance (AMR) if no action
is taken[1]. AMR is the ability of a microorganism (such as a
bacteria) to survive despite being treated with antimicrobial drugs
that should destroy it. As a result, patients with these infections
are more likely to develop complications and up to three times more
likely to die[2].
The spread of CPO represents a major challenge to antimicrobial
stewardship because these organisms have acquired the ability to
produce the enzyme carbapenemase. This enzyme renders carbapenems,
considered a drug of last resort, ineffective. This has brought
about limited effective treatments resulting in high mortality
rates[3].
The BD MAX™ Check-Points CPO assay* provides detection of the
five most common carbapenemase genes in less than 2.5 hours, as
compared to traditional methods that can take up to 24 hours. Early
detection of patients colonized with these organisms can provide
the necessary information to implement proper infection control
measures. This assay replaces an earlier version of the test from
Check-Points, and offers an improved workflow and an additional
target.
"We have been using the Check-Points assay on the BD MAX system
for routine screening of CPO for nearly two years, because it
provides us the information we need to isolate or de-isolate our
high-risk patients shortly after admission," said John Rossen, Assistant Professor of Medical
Microbiology at the University Medical Center, Groningen (UMCG) in
the Netherlands and scientific
secretary of the ESCMID Study Group for Genomic and Molecular
Diagnostics. "This assay has not only improved our
turn-around-time, but it also gives us the confidence that we will
reduce the risk of transmission and outbreak because patient safety
is our number one goal."
Together with BD BBL™ CHROMagar™ CPE plated media* and BD
Phoenix™ CPO detect
panels*, BD provides comprehensive solutions for screening and
infection management to support clinical microbiology laboratories
in their AMR programs.
"The launch of the BD MAX Check-Points CPO assay is another
example of BD's commitment to helping prevent and reduce the spread
of healthcare associated infections (HAIs) and support better
antimicrobial stewardship," said Nikos
Pavlidis, vice president of molecular diagnostics and
women's health for BD.
This assay joins BD's comprehensive healthcare-associated
infections diagnostics portfolio, which aims to reduce transmission
and outbreak of deadly pathogens. The BD MAX system menu also
includes syndromic panels for gastrointestinal infections, as well
as reproductive and sexually transmitted infections, which aid
laboratory professionals in their efforts to deliver diagnostic
results that help enhance patient outcomes, while improving
laboratory efficiency. The instrument also features an open system
capability, allowing for streamlined workflow of laboratory
developed tests and for additional assays via BD partner
collaborations.
*Products are not available for sale in the U.S.
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health by improving medical discovery, diagnostics and the delivery
of care. The company supports the heroes on the frontlines of
health care by developing innovative technology, services and
solutions that help advance both clinical therapy for patients and
clinical process for health care providers. BD and its 65,000
employees have a passion and commitment to help improve patient
outcomes, improve the safety and efficiency of clinicians' care
delivery process, enable laboratory scientists to better diagnose
disease and advance researchers' capabilities to develop the next
generation of diagnostics and therapeutics. BD has a presence in
virtually every country and partners with organizations around the
world to address some of the most challenging global health issues.
By working in close collaboration with customers, BD can help
enhance outcomes, lower costs, increase efficiencies, improve
safety and expand access to health care. In 2017, BD welcomed C. R.
Bard and its products into the BD family. For more information on
BD, please visit bd.com.
About Check-Points
Check-Points
(http://www.check-points.com) is a privately owned diagnostics
company in Wageningen, The
Netherlands and a leading developer and marketer of
molecular assays for gram-negative drug-resistant bacteria.
Check-Points offers a range of IVD and RUO products for the
detection of carbapenemases, ESBLs and AmpCs. In addition, the
Check&Trace product line allows for fast and reliable routine
molecular confirmation and serotyping of Salmonella for food and
veterinary diagnostics.
____________________
[1] O'Neill. Antimicrobial Resistance: Tackling a crisis for the
health and wealth of nations The Review on Antimicrobial Resistance
Chaired, December 2014.
[2] Organisation for Economic Co-operation and Development.
Antimicrobial Resistance in G7 Countries and Beyond: Economic
Issues, Policies and Options for Action. Paris: OECD; 2015.
[3] Centers for Disease Control and Prevention (CDC). Vital
signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal
Wkly Rep. 2013; 62(9):165-170.
Contacts:
Gwen
Gordon
BD Public
Relations
858.812.3724
gwen.gordon@bd.com
Monique N. Dolecki
BD Investor Relations
201.847.5378
monique.dolecki@bd.com
Karin Hendrikx
Management Assistant
+31 (0)317 453 908
karinhendrikx@check-points.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/bd-and-check-points-receive-ce-mark-for-next-generation-resistant-bacteria-screening-test-300582256.html
SOURCE BD (Becton, Dickinson and Company)